SCHEMBL2200970

SCHEMBL2200970

COc1cc(NN)cc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TMPRSS4 Q9NRS4 2/20 0.46
EPHX2 P34913 1/20 0.46
SRC P12931 3/20 0.42
ZAP70 P43403 3/20 0.42
SYK P43405 3/20 0.42
DHFR P00374 1/20 0.42
P2RX1 P51575 1/20 0.41
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
MAPT P10636 3/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8199949 0.92 HDAC3 (0.42) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL8171173 0.83 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL8199952 0.81 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL17671260 0.81 HDAC3 (0.53) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL21965833 0.80 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL998165 0.80 IDO1 (0.46) P2RX1MAPTALDH1A1
SCHEMBL10988446 0.80 ALDH1A1 (0.58) MAPTALDH1A1GAATDP1RAB9A
SCHEMBL5782136 0.80 ALDH1A1 (0.58) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL679095 0.80 ALDH1A1 (0.50) HDAC3HDAC1HDAC2HDAC6TMPRSS4
SCHEMBL8168077 0.79 DHFR (0.46) HDAC3HDAC1HDAC2HDAC6TMPRSS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023036217-A1 ACRYLAMIDE COMPOUND AND USE THEREOF 南京明德新药研发有限公司 2023-03-16 WO disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 HDAC3 276/4885HDAC1 519/4885HDAC2 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.